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Background: Shiga toxin (Stx)-producing Escherichia coli (STEC) infection is associated with hemolytic uremic syndrome
(HUS), the main cause of acute renal failure in early childhood. Stx is essential in the pathogenesis of HUS, which has
been mostly related to Stx2-producing isolates. Very limited data exist on the immune response to STEC in the Brazilian
population. In this study, the prevalence of immunoglobulin G (IgG) antibodies to Stx2 was investigated in sera of
children diagnosed with HUS and of healthy children in the city of São Paulo, Brazil.
Methods: IgG-antibody reactivity to Stx2 was determined by immunoblotting (WB) and enzyme-linked immunosorbent
assay (ELISA) in sera from 13 children with HUS aged 8 months to 6 years and 54 healthy urban children aged 5 months
to 7 years.
Results: A positive immune response to the A and B subunits of Stx2 was observed in 46.1% HUS patients and in 16.6%
healthy individuals by WB. All HUS patients and 62.9% healthy children showed IgG antibodies to the Stx2 A subunit.
The frequency of antibodies to both subunits or only to the A subunit of Stx2 was significantly higher in HUS patients
than controls (p < 0.05). Also, the mean OD value obtained by ELISA was higher in that group. Considering children’s
age, the frequency of reactivity to either the A subunit or both subunits of Stx2 was considerably higher in HUS children
up to three years old compared to controls in the same age range. Moreover, in almost 37% of healthy children, no
immune response to Stx2 was detected independently of the child’s age.
Conclusions: The seroepidemiolgy of anti-Stx2 antibodies was described for the first time in healthy children and
children with HUS in Brazil. The percentage of individuals showing antibodies against Stx2 was higher among
HUS patients than controls, and in spite of the low number of notified HUS cases, STEC strains are circulating in
our settings. In addition, the results obtained also corroborated previous data on the increased sensitivity and
specificity of WB compared to toxin-based enzyme immunoassays.Background
Shiga toxin-producing Escherichia coli (STEC) infection
can induce hemolytic uremic syndrome (HUS), a throm-
botic microangiopathy characterized by acute renal fail-
ure, thrombocytopenia and hemolytic anemia. O157:H7
is the most prominent STEC serotype implicated in ser-
ious outbreaks and sporadic cases of HUS. However, in
the last decade, a wide range of non-O157 STEC serotypes
have shown a significant etiological role in the illness
[1,2]. Worldwide, there is substantial geographic variation* Correspondence: bec.guth@unifesp.br
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unless otherwise stated.in the prevalence of STEC serotypes as well as in the
incidence of HUS. In Brazil, human STEC infections
have been linked mostly to sporadic cases of non-
bloody diarrhea associated mainly with non-O157
strains [3,4]. However, HUS cases associated with O157
as well as non-O157 STEC infections have more re-
cently been described in São Paulo State [5-8]. The
most important virulence property of STEC is its ability
to produce Shiga toxins (Stx), central in the pathogen-
esis of HUS [9]. Stx consist of one enzymatically active
A subunit (32 kDa) linked to a pentamer of B subunits
(7.5 kDa), and are produced during mucosal colonization
and delivered to the circulation [10]. There is increasing
evidence demonstrating the damage caused to vasculartd. This is an Open Access article distributed under the terms of the Creative
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kidneys and gastrointestinal tract [11,12]. The toxin family
contains two major groups that are serologically distinct,
called Stx1 and Stx2. The latter has multiple subtypes or
variants in a range of combinations [13]. Among the Stx
produced by human STEC isolates, Stx2 and Stx2c show
the highest association with severe cases of HUS [14-16].
Protective immunity to STEC infection is likely to re-
sult from the interplay between antibodies that inhibit
colonization of the bowel and those that neutralize Stx
[17]. Experimental and clinical findings suggest that Stx
antibodies can develop a role in the protective immune
response as well as contributing to HUS resistance
[17-19]. However, several epidemiological analyses have
demonstrated that approximately 75% of HUS cases
occur in children less than 5 years old, suggesting that
the disease may be associated with the absence of preexist-
ing immunity in the pediatric population. Neutralization
assay in cell cultures was the earliest approach for detect-
ing antibodies to Stx in human serum. However, some
studies found nonspecific neutralizing activity in this assay
due to a lipoprotein component of the serum [20]. To
overcome these limitations, other assays such as enzyme-
linked immunosorbent assay (ELISA) and Western blot
(WB) have been employed [17,20-22].
Information about the nature and measurement of the
immune response directed against Stx in Brazil is lim-
ited. Palmeira et al. [23] investigated the ability of sera
obtained from healthy adults to neutralize Stx2. Thus,
seroepidemiological data regarding anti-Stx2 antibodies
in the Brazilian population and the use of serodiagnosis
could help to explain the epidemiological profile of the
illness. Therefore, the aim of the present study was to
investigate the prevalence of IgG antibodies to Stx2 in
sera of children diagnosed with HUS and of healthy chil-
dren (control population) in the city of São Paulo, SP,
Brazil, using the accurate and sensitive techniques WB
and ELISA, outlining the first report on the analysis of
Stx antibodies in children in Brazil.
Methods
Human serum samples – patients and controls
Sera were obtained from 13 patients aged 8 months to
6 years, presenting with typical symptoms of HUS. All
patients developed HUS after gastroenteritis, with diar-
rheal prodromes for a median of 6.4 days [8]. The sam-
ples were collected in pediatric intensive care units in
the city of São Paulo during 2001 and 2005. Serum was
collected at admission, in the acute phase of the disease.
The patients were not associated with a STEC outbreak.
Serum samples were collected from 54 urban healthy
children aged 5 months to 7 years with no signs of infec-
tious disease or symptoms of gastrointestinal disorders,
at least for the preceding 30 days, who were seen at theHospital São Paulo outpatient clinic [8]. All serum samples
were stored at −20°C until use. The study was approved by
the Research Ethics Committee at the Universidade Federal
de São Paulo (UNIFESP), and parents gave informed con-
sent for their children to be included in the study.
Stx2
The purified protein was purchased from Tufts New
England Medical Center (Tufts University School of
Medicine) [24].
Immunoblotting (WB)
This assay was adapted from the method reported by
Karmali et al. [17]. Briefly, a standard concentration of
purified Stx2 (3 μg/10 μL) was resolved into its A and B
subunits by SDS-PAGE. Proteins were transferred to
nitrocellulose membranes, which were then cut into lon-
gitudinal strips, blocked with 0.01 M phosphate buffered
saline (PBS), pH 7.2, containing 5% skim milk and 2%
bovine serum albumin (BSA) (blocking buffer), and in-
cubated for 2 h with each serum sample diluted 1:250 in
blocking buffer. After washes in PBS-0.05% Tween-20,
the strips were incubated with a 1:2000 dilution of
peroxidase-conjugated anti-human IgG (Sigma, St Louis,
MO, USA) in blocking buffer. A polyclonal antibody ob-
tained from a rabbit immunized with Stx2 [25] was used
as the positive control for the assay, and this membrane
was incubated with a 1:2000 dilution of peroxidase-
conjugated anti-rabbit IgG (Sigma, St Louis, MO, USA)
in blocking buffer. Antigen-antibody complexes were vi-
sualized with the enhanced chemiluminiscent detection
system (ECL, Amersham Life Science), and positive and
negative responses were qualitatively analyzed. Each
serum sample was assayed at least twice.
ELISA
The assay was based on the method described by Karmali
et al. [19], and prior to its application, a dose–response
curve determined the amount of Stx2 to be used as anti-
gen. Microtiter plates were coated by overnight incubation
at 4°C with 100 μL of 1 μg/mL Stx2 in PBS. Nonspecific
reactions were blocked by incubation with PBS containing
2% BSA at 37°C for 2 h. The wells were washed and incu-
bated with serum samples diluted 1:500 in PBS-BSA at
37°C for 2 h. After washes, the plates were incubated with
1:2000 peroxidase-conjugated anti-human IgG (Sigma, St
Louis, MO, USA) diluted in PBS-BSA at 37°C for 2 h.
Next, 100 μL of substrate solution (0.1 M citrate-
phosphate, pH 5; 1 mg/mL ο-phenylenediamine dihy-
drochloride - Sigma-Aldrich; 30% H2O2) were added to
each well and the plates incubated for 20 min at room
temperature in the dark. The reaction was stopped by the
addition of 50 μL of 4 N sulfuric acid, and optical density
was measured at 492 nm (OD492) using an ELISA
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Figure 2 Frequency of serum reactivity to A and B subunits of
Stx2 according to the age of HUS patients (A) and healthy
children (controls) (B).
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cate at least in two independent experiments and the
mean OD was determined.
Statistical analysis
The significance of differences between the two groups of
children obtained with WB was ascertained by Fisher’s
exact test. Differences were considered to be significant
when p < 0.05. The receiver operating characteristic (ROC)
curve was employed for determining the cut-off value
using the data obtained by ELISA, considering the highest
sensitivity and specificity.
Results
The IgG reactivity profile was first analyzed by WB, and
a positive immune response to the A and B subunits of
Stx2 was observed in six (46.1%) HUS patients and nine
(16.6%) healthy individuals (Figure 1A). All 13 HUS pa-
tients and 34 (62.9%) healthy children showed IgG anti-
bodies to the Stx2 A subunit. Considering the response
to both subunits or only the A subunit, the frequency of
antibodies was significantly higher in HUS patients than
controls (p = 0.032 and p = 0.0055, respectively). Anti-
bodies reacting only with the B subunit were not de-
tected in sera of either HUS patients or healthy children.
A representative IgG response to Stx2 detected by WB
in sera of HUS patients and control subjects is shown in
Figure 1B. It is worth mentioning that considering the
child’s age, the frequency of reactivity either to A sub-
unit or both subunits of Stx2 was considerably higher in
HUS children less than 2 and 2–3 years old compared to
controls in the same age range (Figure 2A and B). Anti-
bodies to A subunit were found in sera of healthy children
of all ages, but the frequency of response was higher in
older children. Moreover, it is interesting to note that inFigure 1 Reactivity profile against Stx2 by Immunoblotting (WB) in HUS patients and healthy children (controls). A) Each bar represents
samples reactive to A and B subunits or only A subunit or non-reactive. * Significant differences were observed between the groups (p = 0.032).
B) Representative immunoblotting strips from HUS patients (lanes 3 and 4) and control sera (lanes 5 and 6) reactive to Stx2. Immunoblotting reaction
was carried out by incubating nitrocellulose membranes, containing purified Stx2 toxin subjected to 12.5% SDS-PAGE, with sera from HUS patients
and healthy individuals followed by incubation with goat anti-human IgG. Lanes 1 and 2 represent positive and negative controls of the assay,
respectively, purified toxin incubated with rabbit anti-Stx2 polyclonal antibody (lane 1) or pre-immune rabbit serum (lane 2), followed by
peroxidase-conjugate anti-rabbit IgG. The arrows represent the A subunit (32 kDa) and B subunit (7.5 kDa) of Stx2.
Table 1 Relationship between results of antibody
response to A and B subunits of Stx2 by Western blot
(WB) and ELISA (E)
WBa No. of sera from HUS No. of sera from controls
E+b E-c E+ E−
A+ / AB+ 10 3 11 23
AB− 0 0 1 19
aA+/AB+, Western blot positive by any parameter whether AB positive or only
A positive; AB−, Western blot negative.
bE+, ELISA positive.
cE−, ELISA negative.
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Stx2 was detected independently of the child’s age.
The serum levels of IgG antibodies reactive to Stx2 as
determined by ELISA are shown in Figure 3, and a wide
range of OD values was observed. The cut-off value was
calculated using the ROC curve, by means of 0.769 for
sensitivity and 0.778 for specificity. Using these criteria,
10 (76.9%) HUS children and 12 (22.2%) healthy individ-
uals had OD values above the cut-off (p = 0.00039). In
addition, the mean OD value was higher in the HUS
group than the controls (0.56 and 0.40, respectively).
Ten HUS patients identified as showing antibodies to
A or AB subunits by WB were also positive by ELISA
(Table 1). In controls, 11 (20.3%) children were reactive
to Stx2 by WB and were also positive by ELISA, and 19
(35.18%) children did not show any response to Stx2
either by WB or ELISA. On the other hand, 23 (42.6%)
healthy children identified as showing IgG to Stx2 by
WB were negative by ELISA, and all of them were only
reactive to the Stx2 A subunit except for one child.
Therefore, relative sensitivity and specificity of WB com-
pared to ELISA were 100 versus 83% and 81 versus 83%,
respectively.
Discussion
STEC infections and HUS are the main cause of acute kid-
ney disease in children under five in some Latin America
countries such as Argentina [16]. In spite of Brazil being
next to Argentina, a low incidence of HUS cases has been
identified so far in Brazil, but the importance of O157 as
an agent of severe disease has also been highlighted [8].
Several reasons can impact the epidemiological profile of
STEC infections and HUS, including climatic conditions,Figure 3 Serum reactivity to Stx2 assessed by ELISA and optical dens
the level of IgG against Stx2 are individually shown and correspond to the
The horizontal line (OD = 0.443) represents the cut-off value.exposure to animal sources of infection or food manufac-
turing and preparation processes [26]. Moreover, it has
been previously proposed that existing anti-Stx antibodies
decrease the risk of HUS. The concept that these anti-
bodies develop a role in protective immunity comes from
experimental and clinical findings [17]. Some studies have
detected an increasing frequency of antibodies to Stx in
the higher age population, which is in general refractory
to HUS [17,18]. In addition, the immunization of labora-
tory animals with the Stx B subunit and fusion proteins
induced neutralizing antibodies that protected mice
against a challenge of E. coli O157:H7 or toxins [27,28].
Although several hypotheses have been proposed to
try to explain the low incidence of HUS cases in Brazil,
no studies have been previously performed on children’s
immune response to Stx in our settings. Moreover, ser-
oepidemiological studies of the immune response to Stx
can be useful for indirectly assessing the degree of ex-
posure to STEC in different populations in different geo-
graphic locations [17]. By using a sensitive assay, WB,
we showed that a high frequency of IgG antibodiesities determined at 492 nm. The optical density values representing
mean OD of two independent assays performed in duplicate wells.
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and in 62.9% of healthy children. Fernández-Brando
et al. [22] detected 67% reactivity to Stx2 by WB in sera
from healthy children in Argentina, where STEC/Stx2 is
highly endemic [16]. In Germany, Ludwig et al. [21] de-
tected an anti-Stx2 response in 71% of patients infected
by a Stx2-producing strain and in 10% of control sera.
Karmali et al. [17] found anti-Stx2 antibodies in 93% of
HUS patients and 46% of urban residents in Canada. In
Germany and Canada, STEC has been implicated in large
outbreaks as well as in sporadic cases of hemorrhagic col-
itis and HUS [29-31]. The observed frequency of anti-
bodies directed to Stx2 can reflect the prevalence of stx2
genes in STEC strains endemic in a particular area.
Despite the high frequency of IgG antibodies directed
to Stx2 identified in the present study, we observed that
the percentage of individuals showing antibodies against
Stx2 was higher among HUS patients than controls (p <
0.05). Also, the mean OD value obtained by ELISA was
higher in that group. Considering that elevated antibody
levels can indicate an active or recent infection [32],
these results suggest that the STEC infection causing
HUS elicited the immune response.
Stx-producing strains were isolated from only three
HUS patients presently studied [8]. Nevertheless, sera
from patients, from whom Stx2-producing O157 and
O165 strains were isolated, showed antibodies to A and
B subunits, and serum of the other patient, from whom
an O26 Stx1-producing strain was recovered, reacted
only with the A subunit of Stx.
It was interesting to observe that ten of 13 HUS patients
and 11 of 34 children reactive to Stx2 by WB were found
to be positive by ELISA, showing a stronger association
between the response detected by WB and ELISA in the
HUS group compared to healthy children. These results
are similar to those described by others and may be due to
the higher levels of antibodies in patients’ sera [22].
The predominance of reactivity to A or B subunit is
variable according to different studies on immune re-
sponse to Stx2. In the present study, HUS patients and
control individuals reacted predominantly with the A
subunit of Stx2, but a positive immune response to A
and B subunits was observed in 46.1% of HUS patients
and 16.6% of controls (p < 0.05), while antibodies react-
ing only to the B subunit were not detected in sera of ei-
ther HUS patients or healthy children. Ludwig et al. [21]
found that 85% of HUS patient serum samples positive
for anti-Stx2 IgG were reactive with the A subunit and
15% recognized the B subunit; in the control group, 45%
of serum samples reacted with the A subunit and 55%
recognized the B subunit. Karmali et al. [17] showed that
70% of serum samples obtained from urban residents in
Canada were reactive to the AB subunits, 7.5% only to
the A subunit and 22.2% only to the B subunit. AmongHUS patients in Canada, all samples reacted with both
the A and B subunits. Fernández-Brando et al. [22] dem-
onstrated that 70% of HUS patients and 47% of controls
in Argentina reacted to the A subunit, and a response to
the B subunit was detected in 72% of HUS patients and
53% of controls. In addition, they also found that anti-
body response to the B subunit tended to decrease faster
than the antibody response to the A subunit. The differ-
ences in response to Stx2 A and B subunits observed in
the studies described so far might be related to several
factors, including differences in exposure, age of patients
and even methodological approaches.
Almost half of the HUS patients (46%) studied herein
were less than two years of age [8], confirming the
higher incidence of HUS in the youngest population. It
is interesting that among the 23 control children up to
two years old, eight showed antibodies to the A subunit,
seven were also positive with regard to the B subunit of
Stx2, and no response was detected among the others.
One may suggest that these antibodies might have been
transferred from their mother across the placenta or by
breast milk [33]. However, the data obtained in this
study cannot support the notion that these transferred
Stx2 antibodies afford protection to children. A relatively
high frequency of serum samples of healthy adults living
in São Paulo City showed neutralizing activity against
Stx2, as demonstrated by Vero cell culture assays [23].
We tested the serum of two HUS patients and two con-
trols, but did not detect neutralizing activity in HUS
serum, although a partial neutralization was observed in
one control serum (data not shown). Scotland et al. [34]
also detected neutralizing activity in control serum against
Stx2. However, this response was attributed to the non-
specific activity of a high-density lipoprotein present in
human serum rather than to specific antibodies [20].
Conclusion
The data presented herein describe for the first time the
seroepidemiolgy of anti-Stx antibodies in healthy children
and children with HUS in Brazil, making an important
contribution to understanding the epidemiology of STEC
infections. The percentage of individuals showing anti-
bodies against Stx2 was higher among HUS patients than
controls, and in spite of the small number of reported
HUS cases, STEC strains are circulating in our settings. In
addition, the results obtained also corroborated the previ-
ous data on the increased sensitivity and specificity of WB
compared to toxin-based enzyme immunoassays.
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